UCB Pharma Limited

208 Bath Road, Slough, Berkshire, SL1 3WE
Telephone: +44 (0)1753 534 655
Medical Information Direct Line: +44 (0)1753 447 690
Medical Information e-mail: Medicalinformationuk@ucb.com
Customer Care direct line: +44 (0) 1773 510123

Patient Information Leaflet last updated on the eMC: 05/08/2011
PIL Dipentum 500mg Tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 05/08/2011 and displayed until Current
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change due to user-testing of patient information
Updated on 17/02/2009 and displayed until 05/08/2011
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change of contra-indications
  • Change to instructions about overdose
  • Change to side-effects
  • Change to drug interactions
  • Change to information about driving or using machinery
Updated on 18/07/2008 and displayed until 17/02/2009
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 14/02/2005 and displayed until 18/07/2008
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 08/02/2005 and displayed until 14/02/2005
Reasons for adding or updating:
  • Change of manufacturer
Updated on 07/02/2003 and displayed until 08/02/2005
Reasons for adding or updating:
  • Update to PIL
Updated on 29/01/2003 and displayed until 07/02/2003
Reasons for adding or updating:
  • Update to PIL

Active Ingredients/Generics

 
   olsalazine sodium